Yeah, it's been good. We can get some investors we don't see all the time here, which is nice.
All right, great. Good afternoon, everyone. Thank you, those of you who've joined in the room and on the phone line as well. My name is Faisal Khurshid, senior biotech analyst at Jefferies. Really pleased to have with us today the management team of Verastem Oncology. Especially pleased to have Michael Bailey in, I think, your first kind of real public showing as the CEO?
Yeah, back in the saddle.
All right. Awesome. Well, Michael, why don't we just start there? I would love if you can just kind of give a little bit of an intro to yourself, the company, and really kind of what encouraged you to take the role.
Yeah. Thank you very much, Faisal, and thanks for having me here. I am really looking forward to this discussion and individual discussions with investors. As far as my background, I am largely business development, kind of commercial type history. I have been with companies like Genentech, AVEO, ImClone. Most recently with ImClone as their CEO for about 11 years, that subsequently sold to LG Chem. Spent about three years with them after that, working on the integration. To your other part of the question, what got me excited about Verastem? I joined the Verastem board in June timeframe, and fast-forward to October 14th, the world really changed for Verastem. As I looked at it as a board member, and then given consideration for taking the seat and the CEO, there was kind of three things that really changed on October 14th. One, a wealth of data.
Two, a really successful financing. Three, obviously the opportunity for me to take over as CEO, and I will kind of unpack each one of those things. The data, and we will spend a little bit more time on the VS-7375 data, really kind of positioned us very clearly as a best-in-class G12D inhibitor. I think, one of the questions with RevMed and all the excitement that Rasonque has brought to the table, and appropriate excitement, is that if you looked at the G12D, which the FDA pulled back the curtain, if you will, their activity was a little less than the G12D, notably because that is a tougher population. Our data in G12D looked really solid that we presented on that day. The other thing I think is really exciting for me and others is the complete responses.
We are seeing single-agent complete responses that I think will be game-changing for this whole space. The second thing I think is the financing. A $250 million raise, very strong demand going into that, I think shows an investor sentiment that is changing and realizing the potential for us kind of going forward. The last thing I think is obviously my leadership and my background being more business development and commercial. What that does really for us is it gives us more optionality. Can we commercialize this by ourselves? Are there BD or partnership opportunities? I think all of those things are on the table.
Got it. I want to touch on both of those points, and we have Dr. Jon Pachter here as well, so we will definitely get into the G12D data. Before we do that, Michael, on that last point that you made on partnership, obviously you are sitting on something very interesting and valuable here with respect to the data that you have generated, and also the robust development plan that you have laid out with plans across all three major indications of pancreatic, colorectal, and lung. How do you think about this from a partnership and value-driving perspective with respect to what does that look like, what does the right timing look like? Just given your background and experience here, would love your comments on that.
Yeah. It is a great question, and the simple answer is not really sure at this point. It is a very rapidly evolving space, and as a company, I think it is really critical to drive shareholder value, to really entertain every single option that is out there. Clearly there is a lot of interest, not only from investors, also from partners. But look at the best, if the best valuation that we can achieve is commercializing ourselves, we need to think about it as what we are really doing here. We would be potentially launching as the first G12D in pancreatic. When you think about it that way, it is a little more manageable than if you take that whole scope of all the opportunities in front of us. That is a little daunting. Just keep in mind, we have to do this stepwise.
Got it. Okay. Makes sense. Let us jump into the data itself then. Jon, I want to give you an opportunity here to talk about, in terms of what you guys have presented, you are putting up some of the best response rates seen for a G12D selective inhibitor. Can you remind us what has enabled that from kind of the basis of the molecule itself?
Yeah, I would love to. I think a few pillars to that. I think first of all, the dual ON/OFF inhibition, which is really important. G12D is mostly in the ON state, but it can go kind of hide out in the OFF state and come back and cycle, and to be able to bind it no matter where it lives is great. It has to be very potent and really equipotent. Ours is about 15 picomolar for both of those states. There is a long residence time, which also really predicted. We saw all this before we saw any clinical data, mind you, and we predicted that it was a good shot at having the best efficacy for patients with KRAS G12D cancers. So the long residence time or slow off rate, about a 24-hour residence time. The third point is it is extremely selective for KRAS G12D.
I think it lets us dose up with good tolerability. KRAS G12D is not responsible for any normal functions in your body, so there are no side effects that would be expected from hitting the target directly, and so that selectivity is really key. Then finally, and I think this has been underestimated, as I look at the RAS space, I think that most inhibitors can not get to maximal inhibition of target for a couple of reasons, depending on the agent. There are some agents where pharmacologically you dose. There is one I am thinking of, you dose at 600, 900, 1,200, you get basically the same exposure. It is flat. It is just a property of the molecule, and that makes it hard to fully hit the target. When you look at waterfalls, you might see on the left side of the waterfall some tumor growth as the best response.
If you're fully hitting the target as we are, we're not seeing that tumor growth as best response when we go up to 900, which is our go-forward dose. In the case of other agents like the pan-RAS inhibitors, pharmacologically, they might be able to achieve better exposure to fully hit the target, but they're limited by the safety profile.
Got it. I want to talk about that, what you just raised on the safety profile, and I'm going to raise this question in sort of a nuanced way, so bear with me. So obviously, your China partner, GenFleet, they've been kind of a half step to one step ahead in terms of data generation. They showed a phase I profile that had this impressive efficacy, but had a good amount of safety baggage with it. You've now shared, as of October, a full set of your phase I data from the U.S. study that looked quite a bit better on the safety profile. For investors, where they worry a little bit about is this kind of a spurious finding? Is this related to limited follow-up?
How can we actually believe that the safety profile is as good as what you're seeing in the U.S. study? What would you say to kind of convince investors of that?
Yeah, I think that at this point, we have enough data that the first thing I'd say is look at our data and take it at face value for what it is. I think that in China, it's not just the RAS space. It's really broader than that. I've talked to other companies that have global trials where there are patients in China and patients ex-China with other targets, and they've also seen poorer tolerability in China. There was an ASCO presentation this year where there were three G12D inhibitors back-to-back, all China trials. The third presentation was our agent, but presented by our partner, GenFleet. In all cases, they had much more toxicity than we see. So, I think we've talked to GenFleet a lot about this. We think one possibility is Chinese traditional medicines are extensively used, not always reported. There could be drug-drug interactions with them.
That is probably a large part of this. I think there is also a higher background of hepatitis in China, which also could be contributing to the safety profile.
Got it. Okay, that makes sense. Then I want to also discuss a little bit on combination strategy, because I think that is something that is super interesting here. So, your China partner, GenFleet, they reported some pretty interesting provocative early data with cetuximab combination of the drug, not only in CRC, where cetuximab is obviously used, but also in pancreatic cancer. Can you address two things? So one is, what is the mechanistic rationale
for that in pancreatic? That is something that surprised investors a little bit. Also, what do you see as kind of the value of a chemotherapy-free approach?
Yeah, those are great questions too. So I think there were, on the preclinical side, there were some really compelling data from Channing Der's lab, who is a leader in the space. In February, there was a really nice paper where they used CRISPR-Cas9 in various pancreatic cancer cells to treat with RAS inhibitors and ask by knocking out one gene at a time, which one, if you knock it out, best augments the efficacy of the RAS inhibitor? EGFR was a top hit, and they saw that whenever they treated pancreatic cancer cell lines with the various RAS inhibitors, they always saw an upregulation of phospho-EGFR as a resistance mechanism. We have generated preclinical data where we have combined VS-7375 with cetuximab in in vivo models. We see regression really nicely when we combine the two.
Clinically, we showed data back in June, some case reports where even at submaximal doses like 400 milligrams, we see that cetuximab, you get a much quicker response and a deep response. It is playing out nicely, but I agree with you. Our partner, GenFleet, showed a 71% response rate they reported in October in pancreatic, and people have been surprised at that. I think your second question is a great one, which is, at some point, the RAS inhibitors, and ours especially, are bringing such strong responses. We are still looking at durability, but that is also looking very good. Do we really need to subject patients to something as toxic as FOLFIRINOX, for example? I think we are all trying to move to a chemo-free regimen.
The cetuximab via VS-7375 arm of our planned phase III trial in frontline pancreatic would exactly be an example of that, and we are looking at that in our phase II and second line pancreatic as well.
Got it. I think you will have some data coming up for this combination across both pancreatic and colorectal, if I remember correctly. I know you have, like, I feel like it is about a dozen data catalysts, like, coming in the next 12 months.
Yes.
Can you just kind of remind us specifically for that combination, the cetux combo in colorectal and pancreatic, when we will be seeing data, and can you just kind of at least high level set expectations for that?
Yeah, I do not want to go into specifics of what data and when exactly, but one thing that we have changed, and it was partly Michael's influence coming in as well, but that is one factor, and also there was a lot of pressure to share data, and we really tried to show discipline getting to October, not dripping out data, waiting until we had all patients, we had all confirmed, all the responses were confirmed that we showed. We showed intent to treat. I think that we are trying to set an example for the field, really. Now that we have done that, we are going to move to a model of presenting more at medical meetings.
That made sense at that time, but now that the data are maturing I think one of the problems with medical meetings initially is you put out an abstract and months later the data are mature and you are publishing, and the abstract lives on. I think in this point, we have been maturing the data for a while. We are now going to turn more to medical meetings. So I think there will be some We have not guided to which meetings, but I think that will be a nice change for us.
Yeah. One thing I will add to that, just as Jon said, in the context of kind of moving from an emerging biotech to potentially becoming a leading biotech, there is a discipline, there is an expectation at the interaction with scientific meetings, not necessarily responding to every request for additional data points. We have presented a very nice data set at this point, and we will build off that in the appropriate way at the appropriate place.
Got it. Yeah, that makes a ton of sense, Michael. To that point, Michael, you guys have a ton of data coming over the next 2027 time period. In your opinion, what are the most critical and value-inflecting of those data sets?
Well, we get this question a lot, and it's kind of like they're all very important. Our goal is to be as broadly applied as possible. We're starting with panc, colon, lung cancer. Obviously, the data that we're targeting with the phase II readouts during the year, I think, are going to be really important because those are going to be the basis of any discussions with the FDA on accelerated approval. So, those are key data, but it will all depend on the strength of the data, and it will determine the path forward that we're going. Right now, we are kind of making all the bets. We'll talk, just not the sidebar, but talk about our cash runway to first half of 2028.
Our cash runway assumes all the phase II data read out, assumes we start phase III data and all that, assumes we get ready for commercialization, assumes we fill out the 301 data. So there's a lot going on in that. This is biotech at the end of the day. Hopefully, they all work out for the benefit of the patients, but you never know.
I think it's important for this audience to really briefly describe the development plan, just to put everything in context. We've started three phase II trials, one in pancreatic, one in lung, one colorectal, that are second line or second line plus. Ideally, each of them could lead to accelerated approval, and that's what we've guided, that the pancreatic and colorectal will fully enroll by the end of this year. The lung is a little bit behind. In 2027, we should see the readouts to those that we could share with the FDA and with investors in due course. So those will be really important because those could lead to accelerated approval. Those are not slowing us down relative to starting phase IIIs that'll all be in frontline in all of the same three indications.
We've guided that we'll start dosing the first patient by the end of this year in the pancreatic study, the phase III, and then the phase IIIs will come next year as a start for lung and colorectal.
Yeah, totally. I think that's a point that, I don't know if everyone kind of totally appreciates, right? The phase IIs, like what you're saying, are like those are shots on goal.
Yep.
But it doesn't change the critical path of doing the phase IIIs?
Yes.
No. It does not change the path.
Got it. Yeah. Okay. I think that's something that has some interesting kind of strategic value also, that you can kind of go to a potential partner and say, "Hey, these are phase IIs. Yeah, it's subject to getting the FDA to agree, but we could get accelerated approval.
Yep.
The phase IIs are all going to be in flight within the next six or so months.
Right.
Do you feel like that is appreciated by investors and by potential partners?
It is a great question, and I think the timing of potential approval is an important part. There are other companies that have started phase IIIs before us. We are going to start our phase III in pancreatic by the end of the year.
Yeah. That is not that far behind. It is like six months.
No, it's not that far behind. We do have the opportunity to leapfrog if, in collaboration with the FDA, they feel that our phase II data is good enough. Again, as I mentioned, we could be the first G12D on the market. But the other thing, kind of back to your other question about what's the important data, I think a lot of the data we put out maybe isn't as appreciated as it could be, which is, one thing that got me really excited is those CRs. Again, single-agent CRs in a refractory setting. No other product has produced single-agent CRs. The importance of single agent goes beyond just a single-agent use. It goes to combinations.
Because when you think about adding on chemotherapy, you're not going to stay on that chemotherapy for potentially your lifetime, which you may have the opportunity to stay on a selective, well-tolerated, effective agent like VS-7375.
Got it. I think the other thing that I think is very powerful from a strategic value perspective is the phase III study in pancreatic that you guys have aligned on. You've put some really interesting design features into that study with respect to overall response as a potential endpoint and crossover. Could you guys talk a little bit about kind of the outcome of the discussions that you had with FDA and kind of getting to this favorable trial design?
Should we take it?
Yeah, you can take it.
Sure. It was a great discussion. They've been a great partner. I think the starting point is we're getting to a world where you can offer patients chemo and not have the option to cross over to a RAS inhibitor.
Right.
I mean, RAS inhibitors work. If they didn't cross over to ours, they could go on to commercial RAS inhibitors. I think that was the starting point, that in the chemo arm I should outline that there are three arms planned for the phase III, and the FDA has aligned with us on this design. The first is our G12D plus an anti-EGFR, which would be a chemo-free regimen, which we were talking about. The second is our G12D with gem/nab-paclitaxel, which would be the chemo combination. The third arm is the chemo, which is a choice up to the investigator between gem/nab-paclitaxel or FOLFIRINOX. I think that if they go on the chemo arm, they have the option to get our drug. Really, in all three arms, they can get our drug, which really should be attractive to patients.
Got it. Yeah, I understand that should kind of help the attractiveness of the study to physicians and to patients. In turn, that should help recruitability of the study as well. I'm really intrigued by the overall response rate endpoint that you have. When you talk about alignment with FDA and this potential to seek a Project FrontRunner type of approval
Right
Can you just give us a little bit more color on what it actually mean in terms of alignment with the FDA? Because it's a broad term that a lot of companies use in slightly different ways.
Well, they agreed to those endpoints. They agreed that PFS and ORR could be co-primary endpoints, and that OS, for the first time, would be a secondary endpoint. That's why I was describing the crossover, is that the OS no longer would be as meaningful, given that patients could get our drug on any of the three arms.
Got it.
Then, right, a la FrontRunner, so those that aren't familiar with Project FrontRunner, the idea is you might get accelerated approval for your response rate, and then follow it up with more of a time-based endpoint, like PFS in this case, for full approval. I don't know that we necessarily hashed that all out. It would be a review issue. We'll see what the data look like. But that design offers up the possibility that there could be accelerated approval for ORR and later for PFS if it's full.
Yeah. Just to build on Jon's point, the FDA is never going to tell you, "We'll give you an approval on this." It's a review issue.
Right.
It's subject to the data, and it's not only got to be statistically significant, but also clinically meaningful.
Sure.
But they were fine with the endpoints. Did they acknowledge that this could be like ORR for accelerated approval with PFS for the full approval?
I don't know that it went there necessarily. I think that the fact that ORR is there brings up that possibility, and that's just really what was groundbreaking was them allowing us to make ORR a co-primary.
Got it. Okay. Just so I understand, this is kind of like one of those situations where it is like they will let you run the study, but you have to kind of come with the data and accelerated approval is-
Right. Exactly right.
a matter of discussion.
Yeah.
Exactly right.
Okay. There's nothing-
This is all subject to the phase II data in particular, any kind of-
Right
accelerated approval, and then Project FrontRunner is based on what we see in the phase III.
Got it. Let me just ask the question a different way, because I think it's important for investors to kind of appreciate this. I think this has caused a little bit of confusion. The extent of the alignment that you have with FDA on response rate as a potential approval endpoint in frontline pancreatic cancer, is the extent of that alignment any different than it would be for any other kind of accelerated approval filing, including a later line setting?
I mean, I think that just, let's just take it at face value that they agreed to 900 as the dose. They agreed to ORR and PFS as co-primaries, and they agreed to OS as a secondary endpoint. I think that's all we should really-
Right
say that we've agreed to.
Maybe said another way, you're kind of getting at, is this a confirmatory study or a pivotal study? That's all subject to the phase II data.
Yeah.
The key thing is, it is a registration phase III study, but whether that ends up being a confirmatory study or whether it ends up being the basis for approval is subject to what we see in our phase II. I think that's got to be really clear to everybody.
Got it. With respect to this idea of Project FrontRunner as an initiative within the oncology division at FDA, is it a project in the sense that like CNPV was a project and you had to get selected and had to kind of be in that pathway? Or is it simply like an avenue that is available once you generate data?
I don't believe it's like a club that you join.
Yeah.
I think it's, we've talked to our regulatory people about that. I think it just reflects the design and their desire to speed things up.
Got it. So it's only the FDA saying, "This is something that can be a path to approval.
Generally, it is a path to approval.
Got it. Okay. Michael, if I can just kind of give you a hard time on something.
Please do.
I feel like Jon probably knows me as the analyst that gives you guys a hard time. When you say that you kind of have the optionality to kind of potentially commercialize yourself, can I just kind of politely push back and ask you to kind of kick the tires on that? Because
Sure
The thing is, you are running these three phase It is an amazing development program, right? You have parallel three phase IIs. You are going to have three phase IIIs. Gigantic undertaking that you are doing, and you are doing it because you have the data to support doing it. I mean, it is like a billion dollars in development capital right there. Why do you think that you could be positioned to do this yourself?
Yeah. Let us kind of break that down. There is one part, you are kind of focusing on the development part. I think what I am introducing here is that we have the commercial capability and now leadership to be able to do this. If you look at my history, I have competed with the biggest of the big in markets that were highly competitive. That doesn't scare me. I think it all depends on the data, selling evidence-based medicine, doing the right thing for the patients. Then there is the financing part of it, which I think is what you are alluding to. How do you afford a billion-dollar program? Well, again, it goes back to the, you take it step by step.
When I talk about optionality, we will get the phase II readouts kind of mid-next year, and we will get a read from the FDA on whether we can get accelerated approval. Those are things that are going to, I would imagine, get investor interest. So our access to capital is going to go up, so we do not have to necessarily go to partners to help us fund this. That is what I mean about optionality. You really have to kind of break it down. We have multiple potential sources of income or revenue to be it, not revenue, but capital to be able to invest in these programs. That is what we want to make sure that we are assessing those opportunities in a way that is going to create shareholder value.
Got it. Okay. That makes a ton of sense. I think that is all the time we have here. Maybe, Mike, if I can just kind of turn it back to you for any closing remarks you want to give.
Yeah. Just to say, I am super excited to be with the team. If you look at what the Verastem team, led by Dan, has put together, it was like a no-brainer. Had to do this because the advances they are seeing for patients, the opportunity here is just tremendous to create shareholder value. I really feel privileged to be able to be part of the team. Thank you.